New Research: Melatonin Use and Age-Related Macular Degeneration Outcomes
Written by Dr. Louis Michaelos, Ophthalmologist & Founder of MacuRest | Last reviewed May 2026
A large observational study from Cleveland Clinic's Cole Eye Institute found that patients who used melatonin were significantly less likely to have AMD progress to advanced stages. Here is what the research shows and what it means for patients taking AREDS2 supplements.
What the Cleveland Clinic Research Found
Researchers at Cleveland Clinic's Cole Eye Institute analyzed electronic health records from over 100,000 adults aged 50 and older, comparing AMD progression rates between melatonin users and non-users. The findings, discussed in Cleveland Clinic's ConsultQD, showed that melatonin users were significantly less likely to progress to late-stage AMD. The results were subsequently published in JAMA Ophthalmology (2024).
As with all observational research, this study establishes association rather than causation. Ongoing clinical trials will determine whether melatonin supplementation directly prevents AMD progression. But the signal is strong enough — and the safety profile of melatonin well-established enough — that many ophthalmologists are beginning to discuss it with their patients.
Why Melatonin and Eye Health Are Connected
The retina is one of the few tissues in the body that produces melatonin independently of the pineal gland. Retinal melatonin peaks at night and directly regulates photoreceptor disc shedding — the process that initiates the overnight repair cycle essential for long-term photoreceptor survival. AMD patients consistently show lower melatonin levels than age-matched controls, suggesting the hormone plays a meaningful role in retinal maintenance.
What This Means for AREDS2 Supplement Users
The standard AREDS2 formula — validated in the National Eye Institute's AREDS2 clinical trial — addresses daytime oxidative protection. It does not include melatonin or address the overnight repair cycle. MacuRest was formulated to fill that gap: combining the full AREDS2-inspired formula with melatonin 5mg in a single evening supplement taken with dinner.
Shop MacuRest — AREDS2 + melatonin, evening formula →
Frequently Asked Questions
What did the Cleveland Clinic study find about melatonin and AMD?
Researchers at Cleveland Clinic's Cole Eye Institute analyzed health records from over 100,000 adults and found that melatonin users were significantly less likely to progress to late-stage AMD. The findings were published in JAMA Ophthalmology (2024). The study establishes association rather than proven causation — randomized controlled trials are ongoing.
Can melatonin slow macular degeneration progression?
Emerging evidence suggests it may. A 2024 JAMA Ophthalmology study of 100,000+ patients found significantly lower AMD progression rates in melatonin users. The retina produces its own melatonin, AMD patients have lower melatonin levels than healthy controls, and melatonin plays a direct role in the overnight retinal repair cycle. Controlled trial data is still accumulating.
Should AMD patients take melatonin in addition to AREDS2?
This is worth discussing with your ophthalmologist. The AREDS2 formula addresses daytime oxidative protection; melatonin may support the overnight repair window that AREDS2 does not address. MacuRest combines both in a single evening supplement. Melatonin has an excellent safety profile at 5mg and is well-tolerated in most adults.
Is the melatonin and AMD research conclusive?
Not yet. The 2024 JAMA Ophthalmology study is observational — it shows association but cannot prove causation. Randomized controlled trials specifically testing melatonin supplementation for AMD progression are needed before definitive clinical recommendations can be made. However, the biological rationale is strong and the safety profile is excellent.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.